Insights
Search Results
Client Highlights
6.02.26
Firm Advises 137 Ventures and BANNER VC on Impulse Space’s $500 Million Series D Financing
On June 2, 2026, Impulse Space, an in-space mobility leader, announced it has raised $500 million in Series D funding, bringing the company’s total capital raised to over $1 billion. The funding will support the company’s hiring and manufacturing growth plans in its efforts to build in-space mobility infrastructure. The funding round was co-led by 137 Ventures and BANNER VC with participation from Founder’s Fund, Lux Capital, and Linse Capital. Wilson Sonsini Goodrich & Rosati advised 137 Ventures and BANNER VC on the transaction.
Client Highlights
6.01.26
Wilson Sonsini Advises Credo on Regulatory Matters Related to Acquisition of DustPhotonics
On May 28, 2026, Credo Technology Group Holding Ltd (Credo), an innovator in providing connectivity at scale through fast, reliable, and energy-efficient system solutions, announced that it has completed its acquisition of DustPhotonics in a transaction valued up to $1.3 billion. DustPhotonics brings industry-leading silicon photonics photonic integrated circuit (SiPho PIC) technology for optical connectivity, deepening Credo’s optical interconnect portfolio across 800G, 1.6T, and 3.2T near-packaged optics (NPO) and co-packaged optics (CPO). Wilson Sonsini Goodrich & Rosati advised Credo on regulatory matters related to the transaction.
Client Highlights
5.14.26
Wilson Sonsini Advises Insider One on Acquisition of Bluecore
On May 13, 2026, Insider One, a leading agentic customer engagement platform, announced its acquisition of Bluecore, a leading retail marketing technology platform serving more than 400 U.S. enterprise brands. Terms of the transaction have not been disclosed. Wilson Sonsini Goodrich & Rosati advised Insider One on the transaction.
Client Highlights
5.05.26
Wilson Sonsini Advises Lattice Semiconductor on $1.65 Billion Acquisition of AMI
On May 4, 2026, Lattice Semiconductor announced it has entered into a definitive agreement with THL Partners to acquire AMI, a leader in platform firmware and infrastructure manageability for cloud and AI. The planned acquisition advances Lattice Semiconductor’s strategy to expand its position in server, AI, and cloud applications spanning hardware, security, manageability, and control. Wilson Sonsini Goodrich & Rosati is advising Lattice Semiconductor on the transaction.
Client Highlights
5.05.26
Wilson Sonsini Represents Investors in Windward Bio’s $165 Million Crossover Financing
On May 4, 2026, Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, announced an upsized $165 million crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The financing also included new investors RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and Harbour BioMed. Wilson Sonsini Goodrich & Rosati represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in the transaction.
Since its launch in January 2025, Windward Bio has in-licensed two clinical-stage assets, raised $365 million, and rapidly advanced both programs in the clinic. The proceeds from this latest financing will significantly extend the company’s cash runway and enable multiple clinical readouts in the next 12 months.
The Wilson Sonsini team that represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in connection with the financing included:
Since its launch in January 2025, Windward Bio has in-licensed two clinical-stage assets, raised $365 million, and rapidly advanced both programs in the clinic. The proceeds from this latest financing will significantly extend the company’s cash runway and enable multiple clinical readouts in the next 12 months.
The Wilson Sonsini team that represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in connection with the financing included:
Client Highlights
3.27.26
Wilson Sonsini Advises Excellergy on $2 Billion Acquisition by Novartis
On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Client Highlights
3.27.26
Wilson Sonsini Advises Reltio on Acquisition by SAP
On March 27, 2026, SAP, a global leader in enterprise applications and business AI, announced its acquisition of Reltio, a leading master data management (MDM) software provider, to help customers make their SAP and non-SAP enterprise data AI-ready. Terms of the deal were not disclosed. Wilson Sonsini Goodrich & Rosati advised Reltio on the transaction.
Client Highlights
12.15.25
Wilson Sonsini Advises Nu Quantum on Series A Financing
On December 10, 2025, Nu Quantum, the category creator and leader in distributed quantum computing, announced it has closed its $60 million Series A funding round, with participation from new investors National Grid Partners, Gresham House Ventures and Morpheus Ventures, and continued support from existing investors Amadeus Capital Partners, IQ Capital, Ahren Capital, Cambridge Enterprise Ventures, East Innovate, NSSIF, and Sumitomo (Presidio Ventures). It is the largest financing round ever raised by a pure-play quantum networking company, and the largest quantum Series A in the UK to date. Wilson Sonsini Goodrich & Rosati advised Nu Quantum on the transaction.
Client Highlights
12.15.25
Wilson Sonsini Advises SpectraWAVE on Acquisition by Philips
On December 15, 2025, Royal Philips announced it has entered into an agreement to acquire Massachusetts-based SpectraWAVE, an innovator in enhanced vascular imaging of coronary arteries, angiography-based physiology assessments, and the use of AI in medical imaging. Wilson Sonsini Goodrich & Rosati is advising SpectraWAVE on the transaction.
Client Highlights
10.17.25
Wilson Sonsini Advises Omeros on Asset Purchase and License Agreement with Novo Nordisk
On October 15, 2025, Novo Nordisk and Omeros Corporation announced that they have entered into a definitive asset purchase and license agreement for the candidate drug zaltenibart (OMS906) in clinical development for rare blood and kidney disorders. Wilson Sonsini Goodrich & Rosati advised Omeros on the transaction.
Client Highlights
10.08.25
Firm Advises Clearway on Acquisitions of Catalina Solar Facility and Deriva Energy’s Solar Portfolio
On October 6, 2025, Clearway Energy, Inc., one of the largest owners of clean energy generation assets in the U.S., announced that it has entered into a binding agreement to acquire a 613MWac portfolio of operating solar assets from Deriva Energy spanning eight states. Clearway also recently announced its acquisition of the 109 MW Catalina Solar facility in Kern County, California. Wilson Sonsini Goodrich & Rosati advised Clearway on the transactions.
Alerts
7.31.25
Jupiter in Retrograde: Executive Order Blocks Transaction by Chinese Company
On July 11, 2025, President Trump took the unusual—but no longer rare—step of issuing a divestment order (the Order) on the basis of a recommendation from the Committee on Foreign Investment in the United States (CFIUS). The Order directs the unwinding of the February 2020 acquisition of Jupiter Systems, LLC (Jupiter) by Chinese Company Suirui Group Co., Ltd. (Suirui). Jupiter is a supplier of video-wall processors and other audiovisual equipment, including to the U.S. government and military. CFIUS reviewed and investigated the transaction and reportedly identified national security risks stemming from Suirui’s ownership of Jupiter, related to the potential compromise of Jupiter products used in military and critical infrastructure environments.